(Helmholtz Zentrum München – German Research Center for Environmental Health) Scientists at the Helmholtz Zentrum München and the Ludwig Maximilians University of Munich have developed a new method of predicting disease progression in gliobastoma patients who have undergone standard treatment. Their findings, published in the journal Oncotarget, show that four miRNAs may hold the vital clue. An application for the corresponding patent has already been filed.
